Advancing our innovative pipeline through collaborations and strategic partnerships
PharmaIN is actively seeking a strategic partner to advance PHIN-214 through clinical development and commercialization.
We are committed to advancing our innovative pipeline by collaborating with pharmaceutical companies, research institutions, and industry leaders.
Why Partner With Us?
- Partnership opportunity to translate compelling clinical activity into blockbuster potential
- The only subcutaneous vasopressor therapy currently in development (phase 1)
- Robust evidence of clinical activity after a single dose with benign safety profile
- Projected global peak sales: $4B at 10% market penetration
